

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Wednesday, February 01, 2006

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L6	L5 and antibod\$	187
<input type="checkbox"/>	L5	L4 and momlv	198
<input type="checkbox"/>	L4	L3 and ltr	2113
<input type="checkbox"/>	L3	L2 and l1	5434
<input type="checkbox"/>	L2	tissue adj specific adj promoter	9641
<input type="checkbox"/>	L1	retrovir\$	49928

END OF SEARCH HISTORY



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI   
[Sign In] [Register]

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search  for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)Display Show Sort by Send to 

All: 1917

Review: 1911



About Entrez  
NCBI Toolbar

[Text Version](#)

Items 1 - 20 of 1917

Page  of 96 [Next](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorials](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)☐ 1: [Huang J, Li X, Hilf R, Bambara RA, Muyan M.](#)[Related Articles, Links](#)

Molecular basis of therapeutic strategies for breast cancer.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):379-96. Review.

PMID: 16375692 [PubMed - indexed for MEDLINE]

☐ 2: [Lee JJ, Swain SM.](#)[Related Articles, Links](#)

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

Semin Oncol. 2005 Dec;32(6 Suppl 7):S22-6. Review.

PMID: 16360719 [PubMed - indexed for MEDLINE]

☐ 3: [Fojo AT, Menefee M.](#)[Related Articles, Links](#)

Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

Semin Oncol. 2005 Dec;32(6 Suppl 7):S3-8. Review.

PMID: 16360716 [PubMed - indexed for MEDLINE]

☐ 4: [Enomoto K, Amano S, Sakurai K, Negishi N.](#)[Related Articles, Links](#)

[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)]

Gan To Kagaku Ryoho. 2005 Oct;32(11):1782-5. Review. Japanese.

PMID: 16315940 [PubMed - indexed for MEDLINE]

☐ 5: [Paisley AN, Drake WM.](#)[Related Articles, Links](#)

Treatment of pituitary tumors: pegvisomant.

Endocrine. 2005 Oct;28(1):111-4. Review.

PMID: 16311417 [PubMed - indexed for MEDLINE]

☐ 6: [Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M.](#)[Related Articles, Links](#)

Targeted agents for the treatment of advanced renal cell carcinoma.

Curr Drug Targets. 2005 Nov;6(7):835-46. Review.

PMID: 16305462 [PubMed - indexed for MEDLINE]

☐ 7: [Akiyama S.](#)[Related Articles, Links](#)

[Genetic alterations and chemoresistance]

Gan To Kagaku Ryoho. 2005 Nov;32(12):1895-901. Review. Japanese.

PMID: 16282723 [PubMed - indexed for MEDLINE]

☐ 8: [Kelly WK, Marks PA.](#)[Related Articles, Links](#)

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.

Nat Clin Pract Oncol. 2005 Mar;2(3):150-7. Review.

PMID: 16264908 [PubMed - indexed for MEDLINE]

☐ 9: [Reddy LH.](#)[Related Articles, Links](#)



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI [?]  
[Sign In] [Register]

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search **PubMed** for **inherited neurological diseases gene therapy review** **Go** **Clear** **Save Search**

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)Display **Summary**Show **20**

Sort by

Send to

**All: 17**

Review: 17



Items 1 - 17 of 17

One page.

☐ **1:** [de Lima MC, da Cruz MT, Cardoso AL, Simoes S, de Almeida LP.](#)[Related Articles, Links](#)

**Liposomal and viral vectors for gene therapy of the central nervous system.**  
Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):453-65. Review.  
PMID: 16101560 [PubMed - indexed for MEDLINE]

☐ **2:** [Huster D, Kuhn HJ, Mossner J, Caca K.](#)[Related Articles, Links](#)

**[Wilson disease]**  
Internist (Berl). 2005 Jul;46(7):731-2, 734-6, 738-40. Review. German.  
PMID: 15915361 [PubMed - indexed for MEDLINE]

☐ **3:** [Romano G.](#)[Related Articles, Links](#)

**Current development of lentiviral-mediated gene transfer.**  
Drug News Perspect. 2005 Mar;18(2):128-34. Review.  
PMID: 15883621 [PubMed - indexed for MEDLINE]

☐ **4:** [Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, Takahashi M.](#)[Related Articles, Links](#)

**The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.**  
Cancer Sci. 2005 Mar;96(3):143-8. Review.  
PMID: 15771616 [PubMed - indexed for MEDLINE]

☐ **5:** [Lowenstein PR, Castro MG.](#)[Related Articles, Links](#)

**Recent advances in the pharmacology of neurological gene therapy.**  
Curr Opin Pharmacol. 2004 Feb;4(1):91-7. Review.  
PMID: 15018845 [PubMed - indexed for MEDLINE]

☐ **6:** [Perlman SL.](#)[Related Articles, Links](#)

**Spinocerebellar degeneration.**  
Expert Opin Pharmacother. 2003 Oct;4(10):1637-41. Review.  
PMID: 14521474 [PubMed - indexed for MEDLINE]

☐ **7:** [Cabrera-Salazar MA, Novelli E, Barranger JA.](#)[Related Articles, Links](#)

**Gene therapy for the lysosomal storage disorders.**  
Curr Opin Mol Ther. 2002 Aug;4(4):349-58. Review.  
PMID: 12222873 [PubMed - indexed for MEDLINE]

☐ **8:** [Barranger JM, Novelli EA.](#)[Related Articles, Links](#)

**Gene therapy for lysosomal storage disorders.**  
Expert Opin Biol Ther. 2001 Sep;1(5):857-67. Review.  
PMID: 11728220 [PubMed - indexed for MEDLINE]

☐ **9:** [Mak W, Ho SL.](#)[Related Articles, Links](#)

**The impact of molecular biology on clinical neurology.**  
Hong Kong Med J. 2001 Mar;7(1):40-9. Review.  
PMID: 11406675 [PubMed - indexed for MEDLINE]

[About Entrez](#)  
[NCBI Toolbar](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorials](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI   
[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books  
Search  for

Limits Preview/Index History Clipboard Details

Display  Show  Sort by  Send to

All: 1 Review: 1

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorials  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources  
Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

☐ 1: [Eur J Cancer](#). 1994;30A(8):1165-71.

[Related Articles, Links](#)

## Replicating vectors for gene therapy of cancer: risks, limitations and prospects.

Russell SJ.

Cambridge Centre for Protein Engineering, MRC Centre, UK.

There are good theoretical arguments for exploring the use of replicating gene-transfer vectors for human cancer therapy. Such vectors should be derived from weakly pathogenic human viruses with initially broad tissue tropism. Coat protein engineering and promoter engineering might be used successfully to narrow the tropism of the vector, enhancing its ability to target tumour cells. Killing of uninfected 'bystander' tumour cells could be achieved through prodrug activation by a vector-encoded enzyme. Rapid elimination of infused vector particles by circulating antiviral antibody would limit access to tumour deposits after repeated administration, but might be circumvented by the use of infectious nucleic acid which is poorly immunogenic [64]. This putative therapeutic strategy is illustrated in Figure 1.

Publication Types:

- [Review](#)

PMID: 7654450 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
Department of Health & Human Services  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jan 30 2006 04:32:28